DelveInsight’s, “Cutaneous Squamous Cell Carcinoma- Pipeline Insight, 2024” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Cutaneous Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Cutaneous Squamous Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Cutaneous Squamous Cell Carcinoma Overview
Cutaneous squamous cell carcinoma (SCC) is a prevalent type of keratinocyte cancer, or non-melanoma skin cancer. It originates from keratin-producing cells in the epidermis, which is the outermost layer of the skin. Cutaneous SCC is characterized by its invasiveness, with cancer cells growing beyond the epidermis. While it can metastasize and become fatal, more than 90% of SCC cases involve numerous DNA mutations in multiple somatic genes. Mutations in the p53 tumor suppressor gene, often caused by ultraviolet (UV) radiation exposure (particularly UVB), are common. Other signature mutations are linked to cigarette smoking, aging, and immune suppression from drugs like azathioprine. Mutations in signaling pathways affect the epidermal growth factor receptor, RAS, Fyn, and p16INK4a signaling. Additionally, β-genus human papillomaviruses (wart virus) are thought to contribute to SCC in immune-suppressed populations, with certain subtypes (5, 8, 17, 20, 24, and 38) also posing risks to immunocompetent individuals.
Cutaneous SCCs typically present as enlarging, scaly, or crusted lumps, often developing within pre-existing actinic keratosis or intraepidermal carcinoma. Various clinical types of invasive cutaneous SCC include:
– Cutaneous horn: Excessive keratin production leading to a horn-like growth.
– Keratoacanthoma (KA): A rapidly growing keratinizing nodule that may resolve without treatment.
– Carcinoma cuniculatum (verrucous carcinoma): A slow-growing, warty tumor on the sole of the foot.
– Marjolin ulcer: SCC developing in a scar or chronic ulcer.
– Multiple eruptive SCC/KA-like lesions: Seen in syndromes such as multiple self-healing squamous epitheliomas of Ferguson-Smith and Grzybowski syndrome.
Diagnosis of cutaneous SCC is based on clinical features and confirmed through a diagnostic biopsy or post-excision pathology. High-risk SCC patients may undergo additional staging investigations, including ultrasound, X-rays, CT scans, MRI scans, and lymph node or tissue biopsies to check for metastasis.
Surgical treatment is the primary approach for cutaneous SCC, with most cases requiring excision with a 3–10 mm margin of normal tissue around the tumor. A skin flap or graft may be needed for repair. There is substantial evidence that rigorous sun protection, at any stage of life, reduces the incidence of SCC. This is particularly crucial for aging, sun-damaged, fair-skinned individuals, immune-suppressed patients, and those with actinic keratoses or a history of SCC.
Cutaneous Squamous Cell Carcinoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Cutaneous Squamous Cell Carcinoma and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Cutaneous Squamous Cell Carcinoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Cutaneous Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
The emerging pipeline products have been categorized under various Molecule types in the report, such as –
-
Oligonucleotide
-
Peptide
-
Small molecule
Learn How the Ongoing Clinical & Commercial Activities will Affect the Cutaneous Squamous Cell Carcinoma Therapeutic Segment @ https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight
Leading Companies in the Cutaneous Squamous Cell Carcinoma Therapeutics Market Include:
-
Incyte Corporation
-
Shanghai Henlius Biotech
-
Novartis
-
Rakuten Medical
-
Morphogenesis
-
Genentech
-
Berg Pharma
-
I-MAB Biopharma
-
Roche
-
Genexine
-
CureVac
Cutaneous Squamous Cell Carcinoma Drugs Profile:
-
HLX 07: Shanghai Henlius Biotech
-
Opzelura: Incyte Corporation
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Cutaneous Squamous Cell Carcinoma Current Treatment Patterns
4. Cutaneous Squamous Cell Carcinoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cutaneous Squamous Cell Carcinoma Late Stage Products (Phase-III)
7. Cutaneous Squamous Cell Carcinoma Mid-Stage Products (Phase-II)
8. Cutaneous Squamous Cell Carcinoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cutaneous Squamous Cell Carcinoma Discontinued Products
13. Cutaneous Squamous Cell Carcinoma Product Profiles
14. Key Companies in the Cutaneous Squamous Cell Carcinoma Market
15. Key Products in the Cutaneous Squamous Cell Carcinoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Cutaneous Squamous Cell Carcinoma Unmet Needs
18. Cutaneous Squamous Cell Carcinoma Future Perspectives
19. Cutaneous Squamous Cell Carcinoma Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/